Nasdaq · Healthcare
KIORA PHARMACEUTICALS INC (KPRX)
As-reported financials and recent SEC filings for KIORA PHARMACEUTICALS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$0
Net income
$-10.8M
Net margin
—
Diluted EPS
$-2.64
ROE
-67.2%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $16.0M | $0 | — | $0 |
| Gross profit | — | — | — | — | — |
| Operating income | $-12.8M | $4.5M | $-12.6M | $-12.3M | $-14.2M |
| Net income | $-10.8M | $3.6M | $-12.5M | $-13.6M | $-13.8M |
| Diluted EPS | $-2.64 | $0.87 | $-3.03 | $-2.32 | $-2.38 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →42026-07-02
View on EDGAR →8-K2026-06-18
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →Largest Healthcare peers
Go deeper on KPRX
Search KIORA PHARMACEUTICALS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.